Troxerutin Zentiva (troxerutin) capsules 300 mg. №60

Description

Troxerutin Zentiva (troxerutin) capsules 300 mg. №60

Composition

active ingredient: troxerutin;

1 capsule contains troxerutin 300 mg;

excipients: macrogol 6000, lactose monohydrate, magnesium stearate; capsule shell: quinoline yellow (E 104), sunset yellow FCF (E 110), titanium dioxide (E 171), gelatin.

Dosage form

Capsules.

Basic physical and chemical properties: yellow hard gelatin capsules. The contents of the capsules are granules, conglomerates of granules or a compressed mass that takes the form of a capsule, from yellow to yellow-brown or yellow-green.

Pharmacological group

Angioprotectors. capillary stabilizing agents. Bioflavonoids. Troxerutin.
ATX code C05C A04.

Pharmacological properties

It is a venoprotective agent. It has venotonic, anti-inflammatory, anti-edematous, angioprotective effect, reduces capillary permeability, fragility. The pharmacodynamic properties of the drug are associated with the participation of bioflavonoids in redox processes. By suppressing hyaluronidase, it stabilizes the hyaluronic acid of the cell membranes and reduces their permeability. Due to its antioxidant activity, it prevents the oxidation of ascorbic acid, lipids, adrenaline. Reduces permeability, fragility of capillaries, prevents damage to the basement membrane of endothelial cells when exposed to various damaging factors. Increases the density of the walls of blood vessels, reduces the exudation of the liquid part of the plasma, diapedesis of blood cells. Inhibits aggregation, increases the degree of erythrocyte deformation.

Indications

Troxerutin Zentiva is used:

• with varicose veins;
•  with chronic venous insufficiency with such manifestations as trophic skin lesions (trophic ulcers, dermatitis), heaviness in the legs;
•  with superficial thrombophlebitis, periphlebitis;
•  with hemorrhoids;
•  with post-thrombotic syndrome;
•  with post-traumatic edema, hematoma;
•  for the prevention of complications after removal of varicose veins of the lower extremities and / or sclerotherapy;
•  as part of the complex therapy of retinopathy in patients with arterial hypertension, diabetes mellitus, atherosclerosis.

Contraindications

Troxerutin Zentiva does not apply:

•  in case of allergy to the active ingredient (methylethylpyridinol);
•  with intolerance to auxiliary components;
•  with gastric ulcer, duodenal ulcer, chronic gastritis in the acute phase;
•  during pregnancy (in the first trimester);
•  with breastfeeding;
•  children under 18 years old.

With caution: in chronic renal failure.

Application during pregnancy and lactation

Use in the first trimester of pregnancy is contraindicated. It is allowed to use it in the II and III trimesters of pregnancy only by the decision of the doctor.
There are no data on the excretion of troxerutin in breast milk; therefore, its use during breastfeeding is not recommended.

Method of administration and dosage

Troxerutin Zentiva is used orally with meals.
The recommended starting dose is 300 mg three times a day. The effect usually develops within two weeks.
Further, therapy is continued at the same dose or reduced to an average therapeutic (300 mg twice a day) or suspended.
The dose can be increased if necessary. The course of treatment is 3-4 weeks.
Maintenance therapy – 300 mg once a day for 3-4 weeks.

Overdose:

• Symptoms: agitation, headache, nausea, “hot flashes” of blood to the face.
• Treatment: gastric lavage, intake of enterosorbents (within an hour after administration), symptomatic treatment.

Side effects:

• immune disorders: hypersensitivity reactions;
• neurological disorders: headache;
• vascular disorders: “hot flashes” of blood to the face;
• gastrointestinal disorders: stomach pain, nausea, diarrhea, vomiting, flatulence, erosive and ulcerative lesions.
• dermatological disorders: erythema, skin rash, pruritus.